[ad_1]
Watch CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
[ad_2]

[ad_1]
Watch CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
[ad_2]

[ad_1]
By Anthony O. Goriainoff
AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
The Anglo-Swedish pharma giant said Lynparza, in combination with abiraterone and prednisone, reduced the risk of disease progression or…
[ad_2]